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Prevalence of chronic obstructive pulmonary 
disease (COPD) in China in 1990 and 2010
Background Chronic obstructive pulmonary disease (COPD) is 
set to become the third most frequent cause of death and also 
the third largest cause of global morbidity by 2020. In China, 
where the population is aging rapidly, COPD has become one of 
the leading causes of disability and a large economic burden. An 
epidemiological assessment of the COPD in China is required, 
with a focus on the number of cases living with disease, main 
determinants of the disease and time trends.
Methods. We systematically searched large Chinese bibliograph-
ic databases and English databases to identify spirometry–based 
epidemiological studies of the prevalence of COPD in China di-
agnosed according to GOLD criteria. We estimated age– and 
gender–specific prevalence of COPD using a multilevel mixed–
effect logistic regression. We also presented the time trends of 
COPD between 1990 and 2010 by age, gender and setting (ur-
ban vs rural).
Findings In 1990, the prevalence of COPD ranged from 0.49% 
(95% CI = 0.29–0.85) in <20 years group to 20.95% (95% 
CI = 14.04–27.04) in> = 80 years group, and the crude preva-
lence for China was 2.70% (95% CI = 1.86–3.51). In 2010, the 
prevalence in <20 years was 0.55% (95% CI = 0.37–1.04) and 
in> = 80 years was 22.89% (95% CI = 18.13–28.96), with the 
crude prevalence for China of 3.84% (95% CI = 3.30–4.77). The 
COPD prevalence in males was about two–fold higher than in 
females, and it increased with increasing age. Between 1990–
2010, the total number of Chinese people living with COPD in-
creased by 66.73%, from 30.90 million (95% CI = 21.28–40.02) 
in 1990 to 51.52 million (95% CI = 44.26–63.93) in 2010. This 
increase was most striking in middle age, and greater in females 
than in males from 30 years up to 64 years. Our estimates, which 
used an independent approach to acquiring data and develop-
ment of analytical methods, and were based on a more complete 
data set, are remarkably similar to those produced recently by 
the GBD 2013 collaboration, differing by only about 5% in the 
estimated number of COPD cases in 1990 and by 1% in 2010.
Conclusions COPD is a highly prevalent disease in China and 
its importance is growing steadily. The number of people living 
with COPD has increased substantially between 1990 and 2010. 
COPD is more frequent in males and in rural areas. Optimised 
primary and secondary prevention and treatment is urgently 
needed to counter this growing trend. Improved epidemiologi-
cal studies will be required to assist development of more effec-
tive strategies of prevention and treatment of COPD in China in 
the next decade and beyond.
Electronic supplementary material: 
The online version of this article contains supplementary material.
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Chronic obstructive pulmonary disease (COPD), characterized by progressive airflow limitation that is 
not fully reversible, is a major cause of chronic morbidity and mortality. It also carries a substantial finan-
cial burden on the society [1–4]. It is estimated that COPD was the sixth most frequent cause of death 
worldwide in 1990, and will become the third by 2020 [5,6]. Within the same time frame, COPD is also 
projected to become the third largest cause of global morbidity [5,7]. Cigarette smoking is the major risk 
factor for COPD, and others include occupational exposures, air pollution, airway hyper–responsiveness 
and asthma, while genetic predisposition may also play some role [8–11]. The startling spread of this 
global health epidemic is occurring as a result of the continuous exposure to COPD risk factors and the 
general aging of the global human population [5,12,13]. In China, where the population is aging very 
rapidly as a result of improved living conditions, urbanization, high economic growth and family plan-
ning [14,15], COPD has become the leading cause of disability [16], resulting in a very large economic 
burden [17–19]. Furthermore, the Chinese population is also at high risk of developing respiratory dis-
eases because of indoor and outdoor pollution [10,20,21]. All the aforementioned factors indicate that 
COPD may present a large challenge for the Chinese health care system in the foreseeable future.
Despite growing evidence of epidemiological and economic impact, the availability of accurate disease 
burden estimates for COPD in China is challenged by the fact that COPD is often underdiagnosed or mis-
diagnosed [1,11]. Up–to–date information about the prevalence of COPD in general population is essen-
tial to inform stakeholders and guide health services allocation [22]. However, the evidence on the prev-
alence of COPD in the Chinese population is quite inconsistent, probably due to variation in case 
definition and diagnostic methods, or study population characteristics [20,23]. The latest Global Burden 
of Disease (GBD) 2013 study revealed a prevalence of COPD of 7.3% (95% CI = 6.7%–7.9%) in Chinese 
population aged 40 years and above in the year 2013 [23]. The GBD 2013 study only included studies 
of high quality, but the limited number of included studies on COPD prevalence in China could have also 
limited the authors' ability to address the burden across the whole country. In addition, COPD becomes 
progressively more common with age, and it could also develop relatively early in life, while previous 
studies in China mainly focused on middle–aged populations [24,25]. It is, therefore, worth exploring 
the burden of COPD across the entire lifespan. Another feature of COPD is that its prevalence is likely 
associated with the greatest socioeconomic inequality in comparison to other common diseases, as COPD 
is generally believed to disproportionally affect the poor [17,22,26]. In China, difference between the ur-
ban and rural setting provides a chance to explore the influence of socioeconomic factors and we are not 
aware of a systematic analysis of urban–rural differences at the national level.
Large Chinese bibliographic databases provide a considerable amount of information that should allow 
studying the epidemiology of disease in China [27,28]. In addition, spirometry method – which is the 
gold standard for the diagnosis of COPD [1,29] – has been widely adopted as an accurate estimate of the 
true burden of COPD in more recent epidemiological studies in China. This provides an opportunity to 
systematically assess the burden of COPD in China based on a standard case definition and diagnostic 
method. In this study, we conducted a comprehensive systematic review, in both Chinese and English 
databases, to analyze published population–based studies of COPD prevalence in China from 1990 on-
wards, based on spirometry as a diagnostic tool. We also presented the time trends of COPD between 
1990 and 2010 by age, gender and setting (urban vs rural).
METHODS
Systematic review and data extraction
We used CNKI, WanFang, CBM and PubMed academic databases to retrieve publications on COPD prev-
alence in China. Parallel searches of the databases were conducted by two independent trained reviewers 
(Chinese databases: XL and WC; English databse: KYC and ANP). The search was limited to studies pub-
lished between 1990 and 2014 (Figure 1). The initial screening of the four databases returned 5237 re-
sults from CNKI, 6151 from the WanFang, 3205 from CBM, and 970 from PubMed, respectively. 382 
studies were retained after excluding duplicates within and between databases, studies with no numerical 
values, studies conducted outside mainland China, review articles, viewpoints, conference abstracts. The 
process is documented in detail in Figure 1.
Further steps included obtaining full–text versions of the retained 382 articles and checking whether they 
met the minimum quality criteria to be used for further analyses and modelling. Studies were subsequent-
ly excluded if they were not prospective in design, not population based, did not report spirometry data 
on COPD prevalence, did not follow the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
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standard of a fixed post–bronchodilator ratio of FEV1/FVC less than 0.7, did not have full text available, 
or contained insufficient or inconsistent data.
Statistical analysis
In the data extraction procedure, individual studies were used to provide multiple data points which con-
tributed to the overall data set. To take into account the sample size and the availability of different data 
points from the same study, a multilevel mixed–effect logistic regression was adopted with a restricted 
cubic spline [30,31]. This was then used to model the COPD prevalence as a function of age. Based on a 
total of 419 data points extracted from 67 studies with spirometry–based diagnosis of COPD, the gen-
der– and age–specific prevalence of COPD in China was estimated. We further estimated the correspond-
ing 95% confidence intervals (CIs) by applying the semiparametric bootstrapping method [32].
The number of gender–specific COPD cases in China in a population 20 years and older in a given year 
was calculated by multiplying the estimated gender–specific prevalence for each 5–year age group with 
the corresponding 5–year population in the same year, available from the United Nations Population Di-
vision (UNPD). This was performed for the years 1990, 2000 and 2010. Then, the gender–specific prev-
alence of COPD for the population aged <20 years was calculated by dividing the aggregated number of 
COPD cases observed in this age group (which was rather small) with the aggregated size of the corre-
sponding population in this age group. This was done across the age groups 0–4, 5–9, 10–14 and 15–19 
years old. The total number of people living with COPD was derived by adding together the numbers of 
males and females living with COPD, and the overall COPD prevalence was calculated by dividing the 
total number of COPD cases with the total size of the population in a given year. All the analyses were 
conducted in R v3.3.0 (R Development Core Team; http://www.R–project.org).
RESULTS
The characteristics of the 67 retained cross–sectional studies are shown in Table S1 and Table S2 in On-
line Supplementary Document: the studies were typically large, published mainly in the past decade 
and led by multi–disciplinary teams of specialists. Geographically, the studies covered all 31 provinces/
municipalities/autonomous regions of mainland China.
The 67 retained studies incorporated 759 461 people tested for COPD, 45 197 of whom were diagnosed 
with COPD using the spirometry method. Across most of the age spectrum in adulthood (20 years and 
Figure 1. PRISMA diagram of study selection. † –The 
large majority was excluded because they were 
duplicate returns of the same reference under different 
search terms or in different databases; the others were 
excluded because they were irrelevant to the topic of 
our study, provided no numerical estimates, or studied 
Chinese populations outside of mainland China. * – 
These are duplicate publications of the same results in 
different journals.
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more), there were large sample sizes providing substantial numbers of data points, except for the very old 
age (>80 years). A total of 47 studies provided the gender–specific prevalence information. Figure 2 shows 
the gender–specific relationship between the COPD prevalence and age, based on all the informative data 
points. Generally, the prevalence of COPD increased steadily with age in both males and females. In males, 
it reached a prevalence of about 25% by the age of 80 years, and in females it was about twice less prevalent. 
Based on the information from the 47 studies, the estimates of COPD prevalence for males and females in 
the years 1990, 2000 and 2010 are shown in Figure 3. Across all three years, the prevalence of COPD was 
consistently greater in males than in females, and the difference was most pronounced in older adults.
A total of 56 studies provided the setting–specific prevalence information. The comparison of COPD 
prevalence between urban and rural dwellers in the years 1990, 2000 and 2010 is presented in Figure 
4. Similar to the comparison of gender–specific prevalence, there was a marked difference in COPD prev-
Figure 4. Chronic obstructive pulmonary disease (COPD) prevalence for urban and rural dwellers in the years 1990, 2000 and 2010, 
with 95% confidence intervals.
Figure 2. Gender and age–specific prevalence of chronic obstructive pulmonary disease (COPD) in China based on 
the information from the systematic review. The size of each bubble is proportional to the sample size, where at 
younger (<20 years) and older (>80 years) groups, the regression lines are based on fewer data points
Figure 3. Chronic obstructive pulmonary disease (COPD) prevalence for males and female in the years 1990, 2000 and 2010, with 
95% confidence intervals.
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alence between urban and rural dwellers, where people in rural areas had higher COPD prevalence than 
those in urban areas.
The overall prevalence of COPD and the number of COPD cases were generated based on the UNPD de-
mographic data, where no demographic information for urban and rural areas was provided, so the set-
ting was not included in the final modelling process. The formula generated from the multilevel mixed–
effect logistic regression is shown below:
ln(odds) =  −13.388 + 0.004 × year + 0.763 × gender + 0.058 × age1 + 0.022 × age2 − 0.083 × age3 + 
0.026 × age4 + ui
Where:
odds = p/(1−p), p indicates the prevalence of COPD
year = calendar year
gender = 1 for males and gender = 0 for females
age1 –age4 are variables created in the process of fitting cubic splines (knots: 34.5, 49.5, 59.8, 71.7, 79.0)
ui = the study level random effect
After applying the estimates of age– and gender–specific COPD prevalence on UN Population Division's 
demographic data, the prevalence of COPD in populations aged <20 years and ≥80 years were calculated. 
From 1990 to 2010, the changes in the gender specific COPD prevalence across all age groups are shown 
in Figure 5 and Table 1. Over the 20 years considered in this analysis, the prevalence of COPD increased 
Table 1. Estimated gender– and age–specific prevalence of chronic obstructive pulmonary disease (COPD) in China in the years 
1990 and 2010
Prevalence of coPD in 1990 (%) Prevalence of coPD in 2010 (%) rate of change  
(%, 1990–2010)
Age 
(years)
Male Female Overall Male Female Overall Male Female Overall
<20 0.65 (0.38–1.14) 0.31 (0.18–0.54) 0.49 (0.29–0.85) 0.72 (0.49–1.36) 0.34 (0.23–0.65) 0.55 (0.37–1.04) 10.77 9.68 12.24
20–24 1.26 (0.83–1.86) 0.59 (0.40–0.87) 0.94 (0.62–1.38) 1.35 (1.06–2.11) 0.64 (0.50–1.02) 1.01 (0.79–1.59) 7.14 8.47 7.45
25–29 1.67 (1.15–2.33) 0.79 (0.55–1.09) 1.25 (0.86–1.73) 1.79 (1.46–2.59) 0.84 (0.69–1.25) 1.33 (1.09–1.93) 7.19 6.33 6.40
30–34 2.22 (1.56–2.93) 1.05 (0.74–1.39) 1.66 (1.17–2.19) 2.37 (2.00–3.20) 1.12 (0.95–1.53) 1.76 (1.49–2.38) 6.76 6.67 6.02
35–39 2.93 (2.09–3.79) 1.39 (0.99–1.80) 2.20 (1.57–2.84) 3.14 (2.73–4.00) 1.49 (1.31–1.93) 2.33 (2.04–2.98) 7.17 7.19 5.91
40–44 3.88 (2.71–5.01) 1.85 (1.29–2.37) 2.90 (2.03–3.75) 4.15 (3.60–5.15) 1.98 (1.75–2.48) 3.09 (2.70–3.85) 6.96 7.03 6.55
45–49 5.18 (3.60–6.53) 2.48 (1.71–3.17) 3.90 (2.71–4.94) 5.54 (4.83–6.71) 2.66 (2.35–3.26) 4.13 (3.62–5.03) 6.95 7.26 5.90
50–54 7.02 (4.92–8.75) 3.40 (2.33–4.29) 5.31 (3.70–6.65) 7.49 (6.66–8.84) 3.64 (3.26–4.30) 5.63 (5.02–6.65) 6.70 7.06 6.03
55–59 9.55 (6.71–11.92) 4.69 (3.25–5.97) 7.23 (5.06–9.08) 10.18 (8.88–11.97) 5.02 (4.41–5.98) 7.68 (6.72–9.07) 6.60 7.04 6.22
60–64 12.77 (9.00–15.64) 6.39 (4.36–7.98) 9.66 (6.74–11.91) 13.58 (11.98–15.74) 6.82 (5.99–8.06) 10.24 (9.02–11.95) 6.34 6.73 6.00
65–69 16.48 (11.69–19.91) 8.42 (5.73–10.45) 12.38 (8.66–15.09) 17.47 (15.40–19.97) 8.98 (7.83–10.52) 13.24 (11.64–15.27) 6.01 6.65 6.95
70–74 20.32 (14.30–24.44) 10.62 (7.16–13.33) 15.23 (10.56–18.62) 21.48 (18.59–24.84) 11.31 (9.65–13.47) 16.29 (14.03–19.04) 5.71 6.50 6.96
75–79 23.95 (17.27–28.67) 12.80 (8.91–15.90) 17.68 (12.57–21.49) 25.26 (22.67–28.42) 13.61 (12.02–15.65) 18.99 (16.94–21.55) 5.47 6.33 7.41
80+ 29.10 (20.17–36.28) 16.38 (10.60–21.86) 20.95 (14.04–27.04) 30.80 (24.85–37.70) 17.51 (13.57–23.02) 22.89 (18.13–28.96) 5.84 6.90 9.26
Total 3.47 (2.40–4.49) 1.88 (1.28–2.47) 2.70 (1.86–3.51) 4.91 (4.22–6.06) 2.69 (2.31–3.37) 3.84 (3.30–4.77) 41.50 43.09 42.22
Figure 5. Estimated gender– and age–specific prevalence of chronic obstructive pulmonary disease (COPD) in 
China in the years 1990, 2000 and 2010.
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slightly in both males and females, which was also indicated in the model formula, where the annual rate 
of change in prevalence on a log odds scale was only 0.004. In 1990, the prevalence of COPD ranged 
from 0.49% (95% CI = 0.29–0.85) in younger people aged under 20 years to 20.95% (95% CI = 14.04–
27.04) for those who were 80 years of age or older, and the overall prevalence was 2.70% (95% CI = 1.86–
3.51). In 2010, the prevalence of COPD ranged from 0.55% (95% CI = 0.37–1.04) in people aged under 
20 years to 22.89% (95% CI = 18.13–28.96) in people aged 80 years and above, with the overall preva-
lence in the Chinese population increasing to the level of 3.84% (95% CI = 3.30–4.77). The COPD prev-
alence between males and females differed consistently from 1990 to 2010, where the prevalence of COPD 
in males was around two–fold higher than in females, and this difference increased with increasing age. 
During 1990 to 2010, the overall prevalence of COPD increased by 42.22%. The most significant in-
creases were in younger population who were under 20 years (12.24%) and older population aged 80 
years and above (9.26%). The increasing rates were similar in males and females.
The estimates of the number of people living with COPD in China are shown in Table 2 and Figure 6. 
With the aging of the Chinese population during 1990–2010, the total number of Chinese people living 
Table 2. Estimated numbers of people living with COPD in China in the years 1990 and 2010, and the rate of change from 1990 to 
2010, by gender and age group
PeoPle living with coPD in 1990 (million) PeoPle living with coPD in 2010 (million) rate of change (%, 
1990–2010)
Age 
(years)
Male Female Overall Male Female Overall Male Female Overall
<20 1.50 (0.88–2.61) 0.66 (0.39–1.15) 2.16 (1.28–3.77) 1.44 (0.98–2.72) 0.57 (0.39–1.09) 2.00 (1.37–3.80) –4.00 –13.64 –7.41
20–24 0.83 (0.55–1.22) 0.36 (0.24–0.53) 1.19 (0.79–1.75) 0.85 (0.66–1.32) 0.36 (0.28–0.58) 1.21 (0.95–1.91) 2.41 0.00 1.68
25–29 0.86 (0.59–1.19) 0.38 (0.26–0.52) 1.23 (0.85–1.71) 0.93 (0.76–1.34) 0.41 (0.34–0.61) 1.34 (1.10–1.95) 8.14 7.89 8.94
30–34 1.00 (0.70–1.32) 0.43 (0.30–0.57) 1.42 (1.00–1.88) 1.12 (0.94–1.51) 0.50 (0.43–0.68) 1.62 (1.37–2.19) 12.00 16.28 14.08
35–39 1.36 (0.97–1.75) 0.58 (0.41–0.75) 1.94 (1.38–2.50) 1.91 (1.66–2.43) 0.87 (0.77–1.13) 2.78 (2.43–3.56) 40.44 50.00 43.30
40–44 1.28 (0.90–1.66) 0.56 (0.39–0.72) 1.85 (1.29–2.38) 2.60 (2.26–3.22) 1.17 (1.04–1.47) 3.77 (3.29–4.70) 103.13 108.93 103.78
45–49 1.34 (0.93–1.69) 0.58 (0.40–0.74) 1.92 (1.33–2.43) 2.68 (2.33–3.24) 1.23 (1.08–1.50) 3.90 (3.42–4.74) 100.00 112.07 103.13
50–54 1.69 (1.19–2.11) 0.73 (0.50–0.92) 2.42 (1.69–3.03) 3.13 (2.79–3.70) 1.42 (1.27–1.67) 4.55 (4.06–5.37) 85.21 94.52 88.02
55–59 2.08 (1.46–2.60) 0.93 (0.65–1.19) 3.01 (2.11–3.78) 4.24 (3.70–4.98) 1.96 (1.72–2.33) 6.19 (5.42–7.31) 103.85 110.75 105.65
60–64 2.21 (1.56–2.71) 1.05 (0.72–1.32) 3.27 (2.28–4.03) 3.80 (3.35–4.40) 1.86 (1.64–2.20) 5.66 (4.99–6.61) 71.95 77.14 73.09
65–69 2.10 (1.49–2.53) 1.11 (0.76–1.38) 3.21 (2.24–3.91) 3.42 (3.02–3.91) 1.74 (1.52–2.04) 5.16 (4.54–5.95) 62.86 56.76 60.75
70–74 1.92 (1.35–2.31) 1.11 (0.75–1.39) 3.03 (2.10–3.71) 3.25 (2.81–3.75) 1.78 (1.52–2.12) 5.03 (4.33–5.87) 69.27 60.36 66.01
75–79 1.30 (0.94–1.55) 0.89 (0.62–1.11) 2.19 (1.56–2.66) 2.54 (2.28–2.86) 1.59 (1.41–1.83) 4.14 (3.69–4.70) 95.38 78.65 89.04
80+ 1.03 (0.71–1.28) 1.03 (0.67–1.38) 2.06 (1.38–2.66) 2.27 (1.83–2.78) 1.90 (1.47–2.50) 4.17 (3.30–5.27) 120.39 84.47 102.43
Total 20.50 (14.22–26.53) 10.40 (7.06–13.67) 30.90 (21.28–40.02) 34.18 (29.37–42.16) 17.36 (14.88–21.75) 51.52 (44.26–63.93) 66.73 66.92 66.73
Figure 6. Estimated numbers of people living with chronic obstructive pulmonary disease 
(COPD) in China by year and age group.
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with COPD increased by 66.73%, from 30.90 (95% CI = 21.28–40.02) million in 1990 to 51.52 (95% 
CI = 44.26–63.93) million in 2010. Throughout this period, the number of COPD cases decreased by 
7.41% in younger people aged under 20 years. The most significant increases were in those who were 
middle–aged (40–49 years and 55–59 years) and at older ages (80 years and above), with rates of change 
in the absolute number of cases in those age–groups above 100%. This increase was greater in females 
than in males from 30 years up to 64 years. In 2010, around two–thirds (66.34%) of the people living 
with COPD were males in China.
DISCUSSION
In this study, by systematically reviewing all published evidence of COPD prevalence databased on spi-
rometry, and applying strict inclusion and exclusion criteria, we presented comprehensive and data–driv-
en estimates of the COPD prevalence in China across the entire age range, and the differences between 
males and females, and urban and rural dwellers in China. As suggested by the Global Initiative for Chron-
ic Obstructive Lung Disease (GOLD), a fixed post–bronchodilator ratio of FEV1/FVC less than 0.7 was 
used as the primary indicator of COPD diagnosis in our study [1]. In the present study, we estimated a na-
tional GOLD–defined COPD prevalence of 2.70% in 1990 and 3.84% in 2010, corresponding to 30.90 
million and 51.52 million people living with COPD in 1990 and 2010 respectively. Our estimate for the 
year 2010 was similar to the estimate presented in the GBD 2013 study, which reported 32.44 million of 
cases in 1990 and 54.79 million of cases in 2013 [23]. Given that the estimates presented in GBD 2013 
study were based on a limited number of studies that were mostly published after 2000, any differences in 
compared COPD number of cases for the year 1990 between these two studies – amounting to 1.54 mil-
lion (or about 5% difference) – may be explained through this lack of data in the GBD 2013 study. Our 
estimate in 2010 is relevant to a point in time 3 years earlier than the GBD 2013 estimate, but based on 
our time trends we would expect our estimate for 2013 to be nearly identical to the GBD estimate, ie, just 
over 54 million cases (with difference of about 1%). In comparison with the results of the GBD 2013 study, 
where a slight decrease of a standardized COPD prevalence was reported between 1990 and 2013 (from 
3.7% to 3.6% overall prevalence in the population), our study observed an overall increase trend of COPD 
prevalence during the two decades between 1990 to 2010 – from 2.70% to 3.84%. Our estimates were 
much in line with the increasing trend of COPD prevalence globally and in the Western Pacific region 
[4,11]. Further analysis from an epidemiological perspective will remain to be required to explore the tem-
poral distribution of COPD prevalence in China. The detailed and systematic estimates of COPD preva-
lence and the number of cases in this study constitute the best currently available basis for policymaking, 
planning, and allocation of health and welfare resources related to the burden of COPD in China. The 
strength of this study arises from several measures that we took to derive the estimates. First, we did a com-
prehensive systematic review and thus included all available studies. Second, of all the measurement meth-
ods, we chose spirometry method as the diagnosis criteria, which served to avoid potential bias arising 
from the variation of measurement tools. Third, the estimate of prevalence was based on study points that 
came from many different locations China, which should ensure representativeness for the whole nation.
In view of the relation between COPD prevalence and age, our study confirms that COPD is a progres-
sive and degenerative disease [11,33]. By estimating the prevalence of COPD in the Chinese population 
over the full age–span, we enabled a public health approach to prevention and treatment of COPD in 
younger population. It was important to note that COPD can also exist in early life, as suggested by pre-
vious studies [24,25]. Younger populations should therefore not be excluded from COPD screening pro-
grams. In our study, although the number of COPD people in <20 years decreased slightly during 1990 
to 2010, the prevalence rate kept increase. Early diagnosis is very important, and disease–modifying ther-
apies that can delay onset could have considerable potential for reducing age–specific prevalence [34].
As expected, the prevalence in males in China was much higher than in females. The excess was most 
likely to be explained by historic patterns of smoking and occupational exposures in Chinese men 
[4,20,35]. From a physiological perspective, it is also widely hypothesized that women are more vulner-
able to the lung–damaging effects of cigarette smoking and biomass fuels, and more prone to develop 
COPD than men when they are at the same level of hazard exposure [35–37]. Our study showed a slight-
ly higher increase of COPD prevalence and of the number of affected individuals in females than in males 
during 1990 and 2010. Based on this trend, it should be expected that prevalence of COPD in Chinese 
women is set to rise in the coming years, partly because of a markedly increasing rate of cigarette smok-
ing in Chinese women [38,39].
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The prevalence of COPD was consistently higher in rural areas than in urban areas in our study. This was 
in contrast with the global estimates, which show that COPD is more frequent in urban areas [4,40]. The 
possible explanation is the variation in classification of rural and urban settings across the world. In Chi-
na, rural areas are generally those with less (or lower–quality) health resources and worse health outcomes 
in comparison to urban areas [41–44]. This urban–rural disparity of COPD prevalence may be associ-
ated with higher smoking rates, but also with prevalent indoor air pollution resulting from the burning 
of wood and other biomass fuels in rural populations [10,26,45]. In addition, lower socioeconomic sta-
tus, lower health resources quality, and worse quality of cigarettes may also have contributed [20,21,26].
A striking increase of 66.73% in the absolute number of estimated COPD cases between 1990 and 2010 
in China was indicated by our analysis. This increase was most prominent in middle–aged and older 
populations. The primary drivers of this increase were longer life expectancy in China, which led to an 
increase of the number of individuals in older age groups, and continuous exposure to risk factors, which 
led to an increase in prevalence among the middle–aged. The estimated number of 51.52 million people 
living with COPD in China in 2010 represents a very large burden for both China and the world, where 
an estimated number of 328 million people have COPD [46,47]. With the current trends of ageing in 
China [14,15], the numbers of individuals affected with COPD will continue to increase, particularly in 
older population. Elderly with medical care needs will constitute a burden on the health care system, and 
support for family caregivers may also be needed [14,44]. In young and middle–aged populations, the 
limitations in their ability to work and their overall mobility may not only lead to a reduced quality of 
life, but also bring an economic challenge to both individuals and the society [18–20]. Even among the 
affected individuals who only have mild symptoms, the effects of COPD may result in impaired quality 
of life. These effects might be profound in many poor settings, where continuous exposure to risk factors 
could accelerate the progress of the disease process [48,49].
Our study also had several potential shortcomings. Significant heterogeneity was seen between all of our 
included studies. This is not surprising, given that China is a diverse country with highly varied culture, 
levels of development and demographic characteristics. Although only studies that adopted the spirom-
etry method and the GOLD criterion were included, in order to reduce the methodological variability, 
heterogeneity may still exist because of the differences among investigators in operating protocols, levels 
of training, adherence to guidelines and variations in implementation of the guidelines. Another possible 
cause for concern is that the results of meta–regression only took into account a limited set of covariates 
(ie, gender, age and urbanicity) because these were the only covariates that were broadly available. The 
scarcity of studies adopting unified definition of other covariates limited our ability to explore more pos-
sible effects. Our estimates, therefore, do not take into account the role of special sub–groups exposed to 
risk factors, such as smokers, household members who are exposed to biomass fuels used for home heat-
ing and cooking, workers with occupational exposures to dust, and people with tuberculosis. This is a 
shortcoming that needs to be addressed in future epidemiological studies of COPD in China. In addition, 
the estimates of prevalence in younger and older age groups were clearly less certain due to scarce data 
and require further refinement. Finally, although GOLD criteria are widely accepted as a diagnostic tool 
for COPD, they are prone to false–negative results among younger and false–positive among older adults, 
which should be taken into account [1,26]. We were also unable to account for the severity of COPD, 
particularly to characterise the burden of the early–stage COPD.
A growing amount of evidence suggests that ambient air pollution is a risk factor for COPD [10,50]. This 
hypothesis may be of particular interest in future COPD epidemiology studies in China, where a dramat-
ic increase in emissions of ambient air pollutants has become a large societal concern [51]. Concern is 
often focused on observed air pollution levels in very large cities, but our analysis didn't find support for 
COPD prevalence being a larger problem in urban as opposed to rural areas.
Our work has implications in both the academic and public health areas. Epidemiological studies that 
are typically available in China on COPD could be designed better, with standardized diagnostic criteria 
and much better presentation of results, taking into account different covariates. Present gaps would ide-
ally be filled by a national disease surveillance system, but this would need considerable and sustainable 
funding and training. Perhaps a more realistic approach would include high–quality epidemiology stud-
ies in large samples, such as Kadoorie study – which provided a large portion of all the data available for 
our study in terms of sample size [52,53]. Adopting standardized measures of COPD, with accurate as-
sessments of the stage and severity of COPD, effectiveness of treatment and clear definition of study pop-
ulation sub–groups in relation to their risk exposure would all help. Currently, most people with COPD 
can only receive a diagnosis in the late stage of disease when symptoms are rather obvious [18]. Although 
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COPD is not a fully reversible disease, the benefits of earlier diagnosis and treatment have been well es-
tablished [11,18]. Efforts should be taken to improve the quality and availability of health care resources 
to address COPD both from the point of prevention, diagnosis and treatment, especially in rural areas 
where the rates of COPD prevalence are higher. In the meanwhile, the importance of primary prevention 
should also be addressed, especially in primary care settings. Health education should focus on targeted 
populations based on the existing evidence [21]. Advocated measures include implementation of tobac-
co–free policies, adequate treatment of asthma and comprehensive strategies on reducing indoor pollu-
tion. [11,18,21].
CONCLUSIONS
In conclusion, results from this study have shown that COPD is a highly prevalent disease in China and 
its importance is growing steadily. The number of people living with COPD has increased substantially 
and nearly doubled between 1990 and 2010. COPD is more frequent in males and in rural areas. Opti-
mal intervention delivery – both in primary and secondary prevention and treatment – is urgently need-
ed to counter this growing trend. Improved epidemiological studies will be required to assist development 
of more effective strategies of prevention and treatment of COPD in China in the next decade and beyond.
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